LEXX insider trading
NasdaqCM HealthcareLexaria Bioscience Corp. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Company website: lexariabioscience.com
LEXX insider activity at a glance
FilingIQ has scored 24 insider transactions for LEXX since May 18, 2022. The most recent filing in our index is dated Mar 17, 2026.
Across the full history, 13 open-market purchases
and 1 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on LEXX insider trades is 55.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for LEXX?
- FilingIQ tracks 24 Form 4 insider transactions for LEXX (Lexaria Bioscience Corp.), covering filings from May 18, 2022 onwards. 1 of those were filed in the last 90 days.
- Are LEXX insiders net buyers or net sellers?
- Across the full Form 4 history for LEXX, 13 transactions (54%) were open-market purchases and 1 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does LEXX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is LEXX in?
- Lexaria Bioscience Corp. (LEXX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $18.04M.
Methodology & sources
Every LEXX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.